中國興業(00132.HK)訂立EPC協議 代價約1.3億人幣
中國興業(00132.HK)公布,在佛山市公共資源交易信息化綜合平台進行的公開招標結束後,公司附屬中岩泰科與中標者中建三局及中譽設計訂立EPC協議,據此,中標者就新能源廠房項目的勘察、設計、採購及施工工程及其他附帶服務獲委任為總承建商。中岩泰科於EPC協議項下應付之代價約為1.3億元人民幣。預期代價之約74.1%將以外部銀行融資撥付,而剩餘約25.9%將以集團之內部資源撥付。
經中岩泰科同意,中標者可將非關鍵性工程分包。預期全部工程將於簽署EPC協議之日起540個曆日內,即於2025年4月30日或之前完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.